Overview

Gender

male

Investor Type

Investment Partner

Dr. Paul L. Kornblith, M.D., is the Medical Advisor at Pittsburgh Life Sciences Greenhouse. Dr. Kornblith is the Chief Executive Officer and Chairman of Almedtrac, Inc. He is a Regional Director at Southwestern Pennsylvania, PA Biotechnology Association. He is an Adjunct Professor at the University of Pittsburgh School of Health and Rehabilitation Sciences. He founded Precision Therapeutics Inc. (PTI) in 1995 and served as its President and Chief Executive Officer until January 2001.

In 1992, Dr. Kornblith was appointed Professor of Neurosurgery, Director of the Brain Tumor Center and Vice Chairman of Neurosurgery for Research and Administration at the University of Pittsburgh Cancer Institute, and the University of Pittsburgh Medical Center, where his research focused on control of brain tumor invasiveness by growth factors and immunologically active cytokines. Dr. Kornblith was appointed the Jeffrey Bergstein Professor of Neurosurgery and Chairman of the Department Neurosurgery at Albert Einstein College of Medicine and Montefiore Medical Center in 1986.

In 1978, he was named the Chief of Surgical Neurology at the National Institutes of Health and directed a multidisciplinary research program in clinical and basic aspects of brain tumor biology. Dr. Kornblith served as the Director of the Clinical Neuro Oncology program at MGH and his research led to the discovery of techniques for the study of human brain tumors in tissue culture as well as their biochemical, biophysical, and ultrastructural characterization. He participated with his colleagues in developing the PET program, as well as a variety of clinical trials of new chemotherapeutic and immunological therapies.

Dr. Kornblith served as acting Clinical Director of the NINCDS and an Assistant Professor of Neurosurgery at Harvard Medical School. He served as Chief of Neurosurgery, Head of the Brain Tumor Center and Clinical Director of the Neurological Institute. He served in the Army Medical Corps in Korea and at Valley Forge Army Hospital. Dr. Kornblith served as a Principal Investigator of an NIH program project in brain tumor biology. His neurosurgical training was with Dr. William Sweet at Massachusetts General Hospital. Dr. Kornblith described the nature of the humoral immune response and developed an assay system for the study of in vitro chemosensitivity. He developed a successful residency training program and focused research efforts in the area of brain tumor growth factors.

Dr. Kornblith serves as the Chairman of Celsense, Inc., Emeritus of Precision Therapeutics Inc. (PTI) and Carmell Therapeutics Corporation. He serves as a Member of Scientific Advisory Board of Cellumen, Inc. He has been Member of Scientific & Medical Advisory Board at Diamyd Medical AB since 2006. He serves on the editorial boards of Neurosurgery, Surgical Neurology, Journal of Neuro-Oncology, and Neurosurgical Quarterly. He served as Chairman of the IRB of the Neurological Institute.

Dr. Kornblith served as a Director of Precision Therapeutics, Inc. He served as Director of The Pennsylvania Biotechnology Association. Dr. Kornblith has over 40 years of experience in clinical trials. He is the author of over 140 peer-reviewed publications, numerous chapters, and four books. Dr. Kornblith authored a book correlating abdominal angiography with his anatomical findings. Dr. Frank Netter's painting of the abdominal blood supply were based were based directly on his anatomic dissections. Dr. Kornblith was awarded the Public Health Service Medal and was awarded the Grass Medal of the Society of Neurosurgeons for his scientific contributions. He interned at Graduate Hospital of the University of Pennsylvania and on completion of his residency at MGH, he was awarded an NIH program project grant for brain tumor biology.

Dr. Kornblith was educated at Temple University and Jefferson Medical College, where he founded the student research society and studied the variant blood supply to the abdominal viscera. He holds M.D.